Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 15, 2025
Optimizing participant and community engagement in cancer genomic sequencing researchNorah L Crossnohere, Anne L R Schuster, Cindy K Blair, et al.JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.Nature Cancer|January 9, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaTejas Jammihal, Renee Maria Saliby, Chris Labaki, et al.Cancer Immunology Research|May 12, 2018
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell CarcinomaRana R McKay, Dominick Bossé, Wanling Xie, et al.Science Immunology|July 24, 2026
Genomic correlates of clinical CAR T cell activityMark B Leick, Baihe Sun, Filippo Birocchi, et al.JCO Precision Oncology|November 9, 2020
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis PairsMichael L Cheng, Mark T A Donoghue, François Audenet, et al.Nature Medicine|December 16, 2022
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Sarah Abou Alaiwi, Wenxin Xu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2020
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease ProgressionMark Bustoros, Romanos Sklavenitis-Pistofidis, Jihye Park, et al.Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.Pageof 6